AbbVie (ABBV) stock has gained 24.0% compared with an increase of 34.3% for the industry in the past year, as seen in the chart below.Image Source: Zacks Investment ResearchAbbVie lost patent protection for its blockbuster immunology drug Humira in the United States in January 2023. Before it lost patent exclusivity, Humira accounted for a significant percentage of AbbVie’s sales, around 37% in 2022. Amgen (AMGN) was the first company to launch its Humira biosimilar. Thereafter, several other biosimilar ver ...